Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease

Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease

Introduction: Anti–glomerular basement membrane (GBM) disease is caused by pathogenic antibodies usually targeting the noncollagenous domain of the α3 chain of type IV collagen and frequently presents as rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage (DAH). Rapid reduction of...

Full description

Saved in:
Bibliographic Details
Main Authors: Vanja Ivković, Ingeborg Bajema, Annette Bruchfeld, Stephen McAdoo, Asheesh Kumar, Richard Klaus, Nele Kanzelmeyer, Maxime Touzot, Georgina Maalouf, Ajay Jaryal, Sanjay Vikrant, Dieter Haffner, Bärbel Lange-Sperandio, David Saadoun, Mårten Segelmark, Andreas Kronbichler
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Kidney International Reports
Subjects:
anti–glomerular basement membrane disease
glomerulonephritis
rituximab
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924034661
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items